Pfizer Overview
Is PFE undervalued? Intrinsic value estimate stands at $24.
Get informed when a big investor buys or sells
+ Follow$24.21
Overvalued by 15.5% based on the discounted cash flow analysis.
Pfizer (PFE) currently reports a DCF fair value of $24. Use the charts on this page to explore Pfizer's DCF fair value history and peer comparisons.
Pfizer's discounted cash flow (DCF) fair value estimate is $24, about 15.5% overvalued versus the current market price. DCF models project future free cash flows and discount them back to today — so the result depends on growth, margin, and discount-rate assumptions. Use it as one valuation lens alongside multiples and peer checks on Stockcircle.
Start with the current DCF fair value of $24, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Pfizer, and consider following PFE for alerts when major investors trade the stock.
Pfizer is classified in the Healthcare sector. On DCF fair value, it currently shows $24. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing PFE with unrelated industries.
